NXTC Stock Summary and Trading Ideas (Nextcure | NASDAQ:NXTC)

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.

Nextcure trades on the NASDAQ stock market under the symbol NXTC.

As of December 26, 2024, NXTC stock price declined to $0.83 with 217,286 million shares trading.

NXTC has a beta of 1.09, meaning it tends to be more sensitive to market movements. NXTC has a correlation of 0.05 to the broad based SPY ETF.

NXTC has a market cap of $23.18 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, NXTC traded as high as $6.48 and as low as $.83.

The top ETF exchange traded funds that NXTC belongs to (by Net Assets): VTI, VXF, IWC.

NXTC has underperformed the market in the last year with a price return of -28.0% while the SPY ETF gained +28.5%. NXTC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -40.4% and -26.7%, respectively, while the SPY returned +5.6% and +0.1%, respectively.

NXTC support price is $.81 and resistance is $.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NXTC shares will trade within this expected range on the day.